Sign In
Buy LLY
$1,131.42
+6.15 (+0.547%)
At Close: Jun 05, 2026
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
08:47am, Thursday, 05'th Sep 2024
A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the co
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
08:15am, Thursday, 05'th Sep 2024
As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound.
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
06:45am, Thursday, 05'th Sep 2024
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 04'th Sep 2024
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:45pm, Wednesday, 04'th Sep 2024
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks presents investors with the better v
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
12:34pm, Wednesday, 04'th Sep 2024
Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points
09:02am, Wednesday, 04'th Sep 2024
Power Inflow occurred at 10:31 am at 958.10. The stock rose to 965.94 at 11:37 am.
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
07:09am, Wednesday, 04'th Sep 2024
Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. The company faced criticism for high prices, supply blockages and the rise of cou
Eli Lilly to license arthritis drug to Egypt's EVA Pharma
06:12am, Wednesday, 04'th Sep 2024
Eli Lilly and Egypt's EVA Pharma have entered into an agreement to license Lilly's rheumatoid arthritis drug in 49 countries in Africa, the companies said on Wednesday.
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
06:00am, Wednesday, 04'th Sep 2024
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in A
Has Eli Lilly Destroyed Hims & Hers Upside?
04:37pm, Tuesday, 03'rd Sep 2024
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market simil
Eli Lilly partner BioAge files for US IPO
04:14pm, Tuesday, 03'rd Sep 2024
BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States.
The Big 3: NVDA, LLY & LIN
01:08pm, Tuesday, 03'rd Sep 2024
Today's Big 3 focuses on industry leaders: Nvidia (NVDA) in Big Tech, Eli Lilly (LLY) in medicine, and Linde (LIN) in energy. Jessica Inskip with StockBrokers.com and Rick Ducat break down the technic
3 Big Winners from the Q2 Earnings Season: LLY, LMT, META
11:16am, Tuesday, 03'rd Sep 2024
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. And during the period, these three companies stole the spotlight.
Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly.
07:09am, Tuesday, 03'rd Sep 2024
While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
